VBI Vaccines Statistics
Total Valuation
VBI Vaccines has a market cap or net worth of 14,341. The enterprise value is 38.13 million.
| Market Cap | 14,341 |
| Enterprise Value | 38.13M |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
VBI Vaccines has 28.68 million shares outstanding. The number of shares has increased by 127.29% in one year.
| Shares Outstanding | 28.68M |
| Shares Change (YoY) | +127.29% |
| Shares Change (QoQ) | +3.44% |
| Owned by Insiders (%) | 0.18% |
| Owned by Institutions (%) | 12.87% |
| Float | 26.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.45 |
| EV / Sales | 4.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.74 |
Financial Position
The company has a current ratio of 0.34
| Current Ratio | 0.34 |
| Quick Ratio | 0.18 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.99 |
| Interest Coverage | -5.84 |
Financial Efficiency
Return on equity (ROE) is -419.59% and return on invested capital (ROIC) is -41.67%.
| Return on Equity (ROE) | -419.59% |
| Return on Assets (ROA) | -29.15% |
| Return on Capital (ROIC) | -41.67% |
| Revenue Per Employee | 69,711 |
| Profits Per Employee | -622,148 |
| Employee Count | 138 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 1.40 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.92% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -99.92% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.43 |
| Relative Strength Index (RSI) | 25.81 |
| Average Volume (20 Days) | 138,949 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, VBI Vaccines had revenue of 9.41 million and -83.99 million in losses. Loss per share was -4.30.
| Revenue | 9.41M |
| Gross Profit | -2.26M |
| Operating Income | -47.55M |
| Pretax Income | -82.99M |
| Net Income | -83.99M |
| EBITDA | -45.58M |
| EBIT | -47.55M |
| Loss Per Share | -4.30 |
Balance Sheet
The company has 12.60 million in cash and 50.71 million in debt, giving a net cash position of -38.12 million or -1.33 per share.
| Cash & Cash Equivalents | 12.60M |
| Total Debt | 50.71M |
| Net Cash | -38.12M |
| Net Cash Per Share | -1.33 |
| Equity (Book Value) | -5.47M |
| Book Value Per Share | -0.22 |
| Working Capital | -51.23M |
Cash Flow
In the last 12 months, operating cash flow was -51.00 million and capital expenditures -484,000, giving a free cash flow of -51.48 million.
| Operating Cash Flow | -51.00M |
| Capital Expenditures | -484,000 |
| Free Cash Flow | -51.48M |
| FCF Per Share | -1.79 |
Margins
| Gross Margin | -24.03% |
| Operating Margin | -505.30% |
| Pretax Margin | -881.79% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -547.03% |
Dividends & Yields
VBI Vaccines does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -127.29% |
| Shareholder Yield | -127.29% |
| Earnings Yield | -859,130.40% |
| FCF Yield | -358,974.31% |
Stock Splits
The last stock split was on April 12, 2023. It was a reverse split with a ratio of 0.0333333.
| Last Split Date | Apr 12, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.0333333 |
Scores
VBI Vaccines has an Altman Z-Score of -13.76. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.76 |
| Piotroski F-Score | n/a |